Cargando…
Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully t...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447929/ https://www.ncbi.nlm.nih.gov/pubmed/28445405 http://dx.doi.org/10.3390/brainsci7050047 |
_version_ | 1783239457766375424 |
---|---|
author | Kanaan, Ahmad Seif Jakubovski, Ewgeni Müller-Vahl, Kirsten |
author_facet | Kanaan, Ahmad Seif Jakubovski, Ewgeni Müller-Vahl, Kirsten |
author_sort | Kanaan, Ahmad Seif |
collection | PubMed |
description | Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff/day (= 100 μL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 × 3 puffs/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting. |
format | Online Article Text |
id | pubmed-5447929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54479292017-05-30 Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols Kanaan, Ahmad Seif Jakubovski, Ewgeni Müller-Vahl, Kirsten Brain Sci Case Report Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff/day (= 100 μL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 × 3 puffs/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting. MDPI 2017-04-26 /pmc/articles/PMC5447929/ /pubmed/28445405 http://dx.doi.org/10.3390/brainsci7050047 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Kanaan, Ahmad Seif Jakubovski, Ewgeni Müller-Vahl, Kirsten Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols |
title | Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols |
title_full | Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols |
title_fullStr | Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols |
title_full_unstemmed | Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols |
title_short | Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols |
title_sort | significant tic reduction in an otherwise treatment-resistant patient with gilles de la tourette syndrome following treatment with nabiximols |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447929/ https://www.ncbi.nlm.nih.gov/pubmed/28445405 http://dx.doi.org/10.3390/brainsci7050047 |
work_keys_str_mv | AT kanaanahmadseif significantticreductioninanotherwisetreatmentresistantpatientwithgillesdelatourettesyndromefollowingtreatmentwithnabiximols AT jakubovskiewgeni significantticreductioninanotherwisetreatmentresistantpatientwithgillesdelatourettesyndromefollowingtreatmentwithnabiximols AT mullervahlkirsten significantticreductioninanotherwisetreatmentresistantpatientwithgillesdelatourettesyndromefollowingtreatmentwithnabiximols |